Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year High - Still a Buy?

Key Points

• 52-week high: Revolution Medicines shares reached $122.12 (last $121.47) on heavy volume, lifting the 50‑day and 200‑day moving averages to $78.75 and $55.33 and valuing the company at about $23.43 billion.
• Analysts maintain a consensus Buy rating (average target $78.94) after multiple upgrades and new coverage, even though that average target sits well below the current share price.
• The company remains unprofitable—last quarter EPS was ($1.61) vs. ($1.39) expected and analysts forecast roughly ($3.49) for the year—while insiders have sold roughly 243,792 shares (~$19.8M) in the past 90 days.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report)'s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $122.12 and last traded at $121.4670, with a volume of 2579112 shares. The stock had previously closed at $119.95.

Analyst Upgrades and Downgrades

Several analysts have issued reports on RVMD shares. JPMorgan Chase & Co. increased their target price on Revolution Medicines from $71.00 to $82.00 and gave the company an "overweight" rating in a research report on Thursday, November 6th. Wolfe Research assumed coverage on Revolution Medicines in a research note on Tuesday, November 18th. They set an "outperform" rating and a $75.00 price objective for the company. Royal Bank Of Canada began coverage on Revolution Medicines in a research note on Monday, November 3rd. They issued an "outperform" rating and a $77.00 target price on the stock. Mizuho began coverage on shares of Revolution Medicines in a report on Tuesday, October 21st. They issued an "outperform" rating and a $90.00 target price for the company. Finally, HC Wainwright increased their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a research report on Thursday, November 6th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $78.94.

Revolution Medicines Price Performance

The firm has a market cap of $23.43 billion, a PE ratio of -23.45 and a beta of 0.99. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. The stock has a 50 day moving average price of $78.75 and a two-hundred day moving average price of $55.33.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same quarter in the previous year, the firm earned ($0.94) EPS. As a group, equities analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 5,447 shares of Revolution Medicines stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total transaction of $418,438.54. Following the completion of the sale, the insider owned 278,600 shares of the company's stock, valued at approximately $21,402,052. The trade was a 1.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jack Anders sold 10,000 shares of the business's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $98.00, for a total value of $980,000.00. Following the sale, the chief financial officer owned 108,065 shares in the company, valued at approximately $10,590,370. The trade was a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 243,792 shares of company stock valued at $19,757,740. 8.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently modified their holdings of the company. Tema Etfs LLC boosted its holdings in shares of Revolution Medicines by 34.7% in the 3rd quarter. Tema Etfs LLC now owns 126,921 shares of the company's stock valued at $5,927,000 after acquiring an additional 32,694 shares during the last quarter. S&CO Inc. lifted its position in Revolution Medicines by 54.5% during the second quarter. S&CO Inc. now owns 14,171 shares of the company's stock valued at $521,000 after purchasing an additional 5,000 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Revolution Medicines during the second quarter valued at $3,639,000. Harbor Capital Advisors Inc. boosted its holdings in Revolution Medicines by 64.7% in the second quarter. Harbor Capital Advisors Inc. now owns 58,323 shares of the company's stock valued at $2,146,000 after purchasing an additional 22,906 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its position in Revolution Medicines by 7.6% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 71,311 shares of the company's stock worth $2,624,000 after purchasing an additional 5,060 shares during the period. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.